# biote Corp.: financial statements, quarterly

BTMD · Nasdaq · CIK 1819253 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/btmd.md) · [Financials](/companies/btmd/financials.md) · [Filings](/companies/btmd/filings.md) · [Insiders](/companies/btmd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/btmd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [45.6](/filings/0000950170-24-125678.md) | [45.7 d](/filings/0000950170-25-039394.md) | [46.8](/filings/0000950170-25-068059.md) | [49.2](/filings/0000950170-25-105800.md) | [51.4](/filings/0001193125-25-272294.md) | [49.8 d](/filings/0001193125-26-106099.md) | [49.0](/filings/0001193125-26-216780.md) | [48.9](/filings/0001193125-26-340364.md) | [48.0](/filings/0001193125-25-272294.md) | [46.4 d](/filings/0001193125-26-106099.md) | [44.9](/filings/0001193125-26-216780.md) | [44.2](/filings/0001193125-26-340364.md) |
| Selling, general and administrative | $m | [23.8](/filings/0000950170-24-125678.md) | [26.2 d](/filings/0000950170-25-039394.md) | [22.9](/filings/0000950170-25-068059.md) | [27.6](/filings/0000950170-25-105800.md) | [23.9](/filings/0001193125-25-272294.md) | [33.0 d](/filings/0001193125-26-106099.md) | [26.7](/filings/0001193125-26-216780.md) | [24.2](/filings/0001193125-26-340364.md) | [26.2](/filings/0001193125-25-272294.md) | [24.7 d](/filings/0001193125-26-106099.md) | [27.8](/filings/0001193125-26-216780.md) | [32.4](/filings/0001193125-26-340364.md) |
| Operating income | $m | [7.6](/filings/0000950170-24-125678.md) | [5.5 d](/filings/0000950170-25-039394.md) | [10.4](/filings/0000950170-25-068059.md) | [6.2](/filings/0000950170-25-105800.md) | [12.2](/filings/0001193125-25-272294.md) | [2.8 d](/filings/0001193125-26-106099.md) | [9.7](/filings/0001193125-26-216780.md) | [10.8](/filings/0001193125-26-340364.md) | [8.3](/filings/0001193125-25-272294.md) | [6.8 d](/filings/0001193125-26-106099.md) | [3.2](/filings/0001193125-26-216780.md) | [(3.5)](/filings/0001193125-26-340364.md) |
| Income tax | $m | [3.9](/filings/0000950170-24-125678.md) | [(2.7) d](/filings/0000950170-25-039394.md) | [2.4](/filings/0000950170-25-068059.md) | [0.1](/filings/0000950170-25-105800.md) | [3.2](/filings/0001193125-25-272294.md) | [(4.7) d](/filings/0001193125-26-106099.md) | [1.6](/filings/0001193125-26-216780.md) | [2.2](/filings/0001193125-26-340364.md) | [(0.8)](/filings/0001193125-25-272294.md) | [3.0 d](/filings/0001193125-26-106099.md) | [0.7](/filings/0001193125-26-216780.md) | [0.3](/filings/0001193125-26-340364.md) |
| Net income | $m | [7.5](/filings/0000950170-24-125678.md) | [7.7 d](/filings/0000950170-25-039394.md) | [(4.2)](/filings/0000950170-25-068059.md) | [(7.1)](/filings/0000950170-25-105800.md) | [10.7](/filings/0001193125-25-272294.md) | [3.7 d](/filings/0001193125-26-106099.md) | [13.7](/filings/0001193125-26-216780.md) | [3.2](/filings/0001193125-26-340364.md) | [8.2](/filings/0001193125-25-272294.md) | [2.0 d](/filings/0001193125-26-106099.md) | [2.3](/filings/0001193125-26-216780.md) | [(6.6)](/filings/0001193125-26-340364.md) |
| Diluted EPS | $ per share | [0.24](/filings/0000950170-24-125678.md) | not reported | [(0.12)](/filings/0000950170-25-068059.md) | [(0.21)](/filings/0000950170-25-105800.md) | [0.33](/filings/0001193125-25-272294.md) | not reported | [0.37](/filings/0001193125-26-216780.md) | [0.10](/filings/0001193125-26-340364.md) | [0.22](/filings/0001193125-25-272294.md) | not reported | [0.06](/filings/0001193125-26-216780.md) | [(0.23)](/filings/0001193125-26-340364.md) |
| Basic EPS | $ per share | [0.25](/filings/0000950170-24-125678.md) | not reported | [(0.12)](/filings/0000950170-25-068059.md) | [(0.21)](/filings/0000950170-25-105800.md) | [0.34](/filings/0001193125-25-272294.md) | not reported | [0.44](/filings/0001193125-26-216780.md) | [0.10](/filings/0001193125-26-340364.md) | [0.26](/filings/0001193125-25-272294.md) | not reported | [0.07](/filings/0001193125-26-216780.md) | [(0.23)](/filings/0001193125-26-340364.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [65.6](/filings/0000950170-23-063027.md) | [89.0](/filings/0000950170-25-039394.md) | [78.8](/filings/0000950170-24-057713.md) | [26.4](/filings/0000950170-24-094529.md) | [38.2](/filings/0000950170-24-125678.md) | [39.3](/filings/0001193125-26-106099.md) | [41.7](/filings/0000950170-25-068059.md) | [19.6](/filings/0000950170-25-105800.md) | [28.0](/filings/0001193125-25-272294.md) | [24.1](/filings/0001193125-26-340364.md) | [5.3](/filings/0001193125-26-216780.md) | [11.2](/filings/0001193125-26-340364.md) |
| Current assets | $m | [118](/filings/0000950170-23-063027.md) | [122](/filings/0000950170-25-039394.md) | [114](/filings/0000950170-24-057713.md) | [61.8](/filings/0000950170-24-094529.md) | [70.0](/filings/0000950170-24-125678.md) | [68.1](/filings/0001193125-26-106099.md) | [68.7](/filings/0000950170-25-068059.md) | [49.5](/filings/0000950170-25-105800.md) | [57.1](/filings/0001193125-25-272294.md) | [54.7](/filings/0001193125-26-340364.md) | [36.4](/filings/0001193125-26-216780.md) | [43.0](/filings/0001193125-26-340364.md) |
| Total assets | $m | [150](/filings/0000950170-23-063027.md) | [155](/filings/0000950170-25-039394.md) | [160](/filings/0000950170-24-057713.md) | [92.9](/filings/0000950170-24-094529.md) | [101](/filings/0000950170-24-125678.md) | [122](/filings/0001193125-26-106099.md) | [123](/filings/0000950170-25-068059.md) | [105](/filings/0000950170-25-105800.md) | [111](/filings/0001193125-25-272294.md) | [108](/filings/0001193125-26-340364.md) | [89.0](/filings/0001193125-26-216780.md) | [102](/filings/0001193125-26-340364.md) |
| Current liabilities | $m | [25.1](/filings/0000950170-23-063027.md) | [22.2](/filings/0000950170-25-039394.md) | [24.1](/filings/0000950170-24-057713.md) | [46.3](/filings/0000950170-24-094529.md) | [46.5](/filings/0000950170-24-125678.md) | [51.5](/filings/0001193125-26-106099.md) | [48.5](/filings/0000950170-25-068059.md) | [50.5](/filings/0000950170-25-105800.md) | [56.3](/filings/0001193125-25-272294.md) | [45.0](/filings/0001193125-26-340364.md) | [28.2](/filings/0001193125-26-216780.md) | [30.1](/filings/0001193125-26-340364.md) |
| Total liabilities | $m | [201](/filings/0000950170-23-063027.md) | [192](/filings/0000950170-25-039394.md) | [205](/filings/0000950170-24-057713.md) | [235](/filings/0000950170-24-094529.md) | [228](/filings/0000950170-24-125678.md) | [225](/filings/0001193125-26-106099.md) | [208](/filings/0000950170-25-068059.md) | [184](/filings/0000950170-25-105800.md) | [177](/filings/0001193125-25-272294.md) | [158](/filings/0001193125-26-340364.md) | [137](/filings/0001193125-26-216780.md) | [160](/filings/0001193125-26-340364.md) |
| Long-term debt | $m | [108](/filings/0000950170-23-063027.md) | [107](/filings/0000950170-25-039394.md) | [105](/filings/0000950170-24-057713.md) | [104](/filings/0000950170-24-094529.md) | [103](/filings/0000950170-24-125678.md) | [101](/filings/0001193125-26-106099.md) | [99.8](/filings/0000950170-25-068059.md) | [98.5](/filings/0000950170-25-105800.md) | [97.1](/filings/0001193125-25-272294.md) | [95.8](/filings/0001193125-26-340364.md) | [94.4](/filings/0001193125-26-216780.md) | [118](/filings/0001193125-26-340364.md) |
| Current portion of debt | $m | [6.3](/filings/0000950170-23-063027.md) | [6.3](/filings/0000950170-25-039394.md) | [6.3](/filings/0000950170-24-057713.md) | [6.3](/filings/0000950170-24-094529.md) | [6.3](/filings/0000950170-24-125678.md) | [6.3](/filings/0001193125-26-106099.md) | [6.3](/filings/0000950170-25-068059.md) | [6.3](/filings/0000950170-25-105800.md) | [6.3](/filings/0001193125-25-272294.md) | [6.3](/filings/0001193125-26-340364.md) | [6.3](/filings/0001193125-26-216780.md) | [3.1](/filings/0001193125-26-340364.md) |
| Shareholders' equity | $m | [(40.5)](/filings/0000950170-23-063027.md) | [(29.4)](/filings/0000950170-25-039394.md) | [(36.0)](/filings/0000950170-25-068059.md) | [(143)](/filings/0000950170-25-105800.md) | [(130)](/filings/0000950170-24-125678.md) | [(106)](/filings/0001193125-26-106099.md) | [(90.0)](/filings/0000950170-25-068059.md) | [(85.1)](/filings/0000950170-25-105800.md) | [(72.8)](/filings/0001193125-25-272294.md) | [(58.5)](/filings/0001193125-26-340364.md) | [(56.1)](/filings/0001193125-26-216780.md) | [(65.8)](/filings/0001193125-26-340364.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [0.2 d](/filings/0000950170-24-125678.md) | [7.0 d](/filings/0000950170-25-039394.md) | [7.4](/filings/0000950170-25-068059.md) | [9.9 d](/filings/0000950170-25-105800.md) | [15.6 d](/filings/0001193125-25-272294.md) | [12.4 d](/filings/0001193125-26-106099.md) | [6.5](/filings/0001193125-26-216780.md) | [7.1 d](/filings/0001193125-26-340364.md) | [14.1 d](/filings/0001193125-25-272294.md) | [7.6 d](/filings/0001193125-26-106099.md) | [3.9](/filings/0001193125-26-216780.md) | [(1.2) d](/filings/0001193125-26-340364.md) |
| Capital expenditure | $m | [0.5 d](/filings/0000950170-24-125678.md) | [(0.2) d](/filings/0000950170-25-039394.md) | [0.7](/filings/0000950170-25-068059.md) | [2.5 d](/filings/0000950170-25-105800.md) | [1.6 d](/filings/0001193125-25-272294.md) | [1.7 d](/filings/0001193125-26-106099.md) | [1.6](/filings/0001193125-26-216780.md) | [1.8 d](/filings/0001193125-26-340364.md) | [0.5 d](/filings/0001193125-25-272294.md) | [1.1 d](/filings/0001193125-26-106099.md) | [0.4](/filings/0001193125-26-216780.md) | [2.6 d](/filings/0001193125-26-340364.md) |
| Dividends paid | $m | [1.0 d](/filings/0000950170-24-125678.md) | [1.1 d](/filings/0000950170-25-039394.md) | [0.1](/filings/0000950170-25-068059.md) | [4.1 d](/filings/0000950170-25-105800.md) | [0.5 d](/filings/0001193125-25-272294.md) | [0.1 d](/filings/0001193125-26-106099.md) | [0.7](/filings/0001193125-26-216780.md) | [0.9 d](/filings/0001193125-26-340364.md) | [0.0 d](/filings/0001193125-25-272294.md) | [0.1 d](/filings/0001193125-26-106099.md) | [0.4](/filings/0001193125-26-216780.md) | [0.6 d](/filings/0001193125-26-340364.md) |
| Share repurchases | $m | not reported | not reported | [4.1](/filings/0000950170-25-068059.md) | [1.5 d](/filings/0000950170-25-105800.md) | [0.0 d](/filings/0001193125-25-272294.md) | [0.0 d](/filings/0001193125-26-106099.md) | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-106099.md) | [1.1](/filings/0001193125-26-216780.md) | [4.8 d](/filings/0001193125-26-340364.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [7.6](/filings/0000950170-23-063027.md) | [17.6](/filings/0000950170-24-057713.md) | [20.7](/filings/0000950170-24-094529.md) | [31.0](/filings/0000950170-24-125678.md) | [34.6](/filings/0000950170-25-068059.md) | [33.1](/filings/0000950170-25-105800.md) | [32.3](/filings/0001193125-25-272294.md) | [37.0](/filings/0001193125-26-216780.md) | [31.7](/filings/0001193125-26-340364.md) | [36.7](/filings/0001193125-25-272294.md) | [36.0](/filings/0001193125-26-216780.md) | [28.6](/filings/0001193125-26-340364.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.